A spirin affords cardioprotection inducing a complete and permanent defect in the capacity of platelets to generate thromboxane A 2 (TXA 2 ) through the acetylation of serine 529 of cyclooxygenase-1 (COX-1). 1, 2 Because of a nonlinear relationship of inhibition of platelet TXA 2 generation with inhibition of TXA 2 -mediated platelet aggregation, an excess of 95% inhibition of COX-1 activity is required to influence platelet function. 3 In fact, even tiny concentrations of TXA 2 have been shown to cause platelet activation. Thus, 10 nmol/L of the TXA 2 mimetic U46619 induces platelet adhesion and shape change, 4 and in the presence of a subthreshold concentration of collagen, U46619 (0.5 to 10 nmol/L) causes platelet aggregation. 5 Recently, Maree et al 6 showed that many patients who are treated with low-dose enteric-coated aspirin (75 mg) for secondary prevention of cardiovascular events have persistent elevated serum TXB 2 levels (Ͼ2.2 ng/mL), which translates into a more frequent occurrence of arachidonic acid (AA)-induced platelet aggregation. Reduced bioavailability of aspirin 6 and genetic variants in COX-1 7 may participate in the intersubject variable response to aspirin. The recent recognized capacity of platelets to make proteins de novo 8 paves the way to identify new mechanisms involved in aspirin failure to cause complete and persistent suppression of platelet COX-1 activity in some individuals.
Thus, in the present study, we assessed, in vitro, the hypothesis that de novo synthesis of COX-1 could account for TXA 2 biosynthesis in platelets in which the activity of preformed COX-1 was blocked by pretreatment with aspirin in vitro.
Materials and Methods
Healthy volunteers (nϭ9 to 22; mean age 40Ϯ5 years) who provided blood for the study did not assume aspirin or nonsteroidal antiinflammatory drugs (NSAIDs) within 10 days before donation. Platelet-rich plasma (PRP) 9 was incubated for 30 minutes at 37°C without or with 0.3 mmol/L of aspirin. Platelets were then isolated from plasma as described previously 9 and resuspended in RPMI 1640 supplemented with 0.5% FCS. Platelet suspension contained Ͻ1 leukocyte per 10 000 platelets. Unless otherwise indicated, 5ϫ10 8 platelets/mL were used for each experimental point. Mononuclear cells were separated from whole blood containing heparin (10 IU/mL) by Ficoll-Paque and stimulated for 12 hours with lipopolysaccharide (LPS; 10 g/mL). 10 Aspirin-treated or untreated platelets were incubated in the absence or in the presence of fibrinogen (0.38 mg/mL) alone or with thrombin (1 U/mL), for different times, at 37°C. The reaction was stopped by immediate centrifugation and supernatants stored at Ϫ80°C. In some experiments, exogenous AA (10 mol/L) was added at different times, and the incubation carried on for an additional 10 minutes. In selected experiments, the following translation or signal transduction inhibitors, cycloheximide (1 mmol/L), puromicine (500 mol/L), rapamycin (100 nmol/L), actinomycinD (1 mmol/L), staurosporine (10 mol/L), wortmannin (100 nmol/L), LY294002 (10 mol/L), AG490 (10 mol/L), or vehicle (dimethylsulfoxide 0.1%), were added to platelets 10 minutes before starting incubation with fibrinogen and thrombin. The effects of a selective and reversible COX-1 inhibitor (P6), 11 aspirin, and 2 selective COX-2 inhibitors, rofecoxib and etoricoxib, were studied by their addition to platelets immediately before starting the incubation with thrombin and fibrinogen. In platelet supernatants, TXB 2 was evaluated by radioimmunoassay, 1 reflecting TXA 2 generation. All reagents were from Sigma-Aldrich.
RT-PCR of COX-1 and COX-2 and radiolabeling of platelets and immunoprecipitation of COX-1 are described in the expanded Material and Methods section in the online data supplement, available at http://circres.ahajournals.org.
Statistical Analysis
Data, presented as meansϮSEM, were analyzed by repeatedmeasurement ANOVA. PϽ0.05 was considered statistically significant.
Results and Discussion
Aspirin (0.3 mmol/L) pretreatment of PRP of healthy individuals was associated with an almost complete suppression of TXA 2 generation in washed platelets incubated for 30 minutes with fibrinogen (0.38 mg/mL) and thrombin (1 U/mL; 162.3Ϯ30.5 versus 0.1Ϯ0.03 ng/mL; nϭ9). A significant increase of TXA 2 generation was detected in supernatants of aspirinated platelets cultured for 24 hours with fibrinogen and thrombin (3Ϯ0.8 ng/mL; nϭ22) but not in resting platelets or when they were incubated with fibrinogen alone ( Figure 1A Table) . The generation of TXA 2 in aspirinated platelets was significantly increased in the presence of exogenous AA (10 mol/L; at 0.5 versus 24 hours: 2Ϯ0.7 and 25Ϯ7 ng/mL [nϭ3]; Pϭ0.0004 and PϽ0.0001 versus the same time points without exogenous AA; supplemental online Figure) . These concentrations of TXA 2 are biologically active 4 -6 and, in the presence of other platelet agonists, may further boost platelet responses. 4, 5 As shown in Figure 1B , TXA 2 generation was depressed in a concentration-dependent fashion by P6, a COX-1 inhibitor, 11 and by aspirin (added de novo immediately before starting incubation) but not by etoricoxib or rofecoxib, 2 COX-2 inhibitors. The potency of aspirin to inhibit the recovery of TXA 2 synthesis in aspirinated platelets at 24 hours of incubation (IC 50 , 22 mol/L; 95% CI, 9 to 56) was significantly lower than that found at 30 minutes (IC 50 , 4.5 mol/L; 95% CI, 3.8 to 5.5; data not shown). This led us to hypothesize that time-dependent de novo synthesis of COX-1 protein could account for recovered COX-1 activity. Consistently, we demonstrated that TXA 2 biosynthesis in aspirinated platelets stimulated with fibrinogen and thrombin occurred by a regulated pathway for protein translation. In fact, it was prevented by puromycin, which causes the premature release of nascent polypeptide chains, cycloheximide, which blocks the translocation reaction on ribosomes and rapamycin, a bacterially derived immunosuppressant that inhibits the translation of a specific subset of mRNAs. In contrast, actinomycin D, a transcriptional inhibitor, did not affect the biosynthesis of this prostanoid. In addition, we found that inhibitors of phosphatidylinositol 3-kinase, LY294002 and wortmannin, also blocked TXA 2 recovery, indicating that this response is phosphatidylinositol 3-kinase dependent. In contrast, AG-490, a tyrosine kinase inhibitor, and staurosporine, a protein kinase C inhibitor, did not significantly affect TXA 2 generation in this setting ( Figure  1C) . The apparent reduction obtained by staurosporine may be attributable to its possible interaction with phosphatidylinositol 3-kinase.
Thus, aspirin-treated platelets recovered their ability to produce TXA 2 via a signal-dependent de novo protein synthesis. We hypothesized that this protein could be COX-1 itself. First, we explored whether platelets contained mRNA for COX isozymes. As shown in Figure 2A , COX-1, but not COX-2, mRNA can be detected by RT-PCR in resting platelets (lanes 1 and 3) as well as in platelets incubated for Figure 1 . Aspirin-treated platelets recover COX-1-dependent capacity to synthesize TXA 2 : Role of translational and signal transduction pathways. A, PRP from healthy donors was treated for 30 minutes at 37°C with aspirin (0.3 mmol/L), and washed platelets were incubated for 0.5 or 24 hours without or with fibrinogen (0.38 mg/mL) alone or with thrombin (1 U/mL), and TXA 2 biosynthesis was assessed. 1 B, Aspirin-treated platelets, 5ϫ10 8 /mL, activated by thrombin and fibrinogen were incubated for 24 hours without or with aspirin, P6 (a reversible and selective COX-1 inhibitor), 11 and 2 selective COX-2 inhibitors, etoricoxib and rofecoxib, and with inhibitors of translation and signal transduction (C).
3 hours in the presence of both fibrinogen and thrombin (lanes 2 and 4). As positive control, COX-2 mRNA was detected in purified human mononuclear cells activated with LPS. To explore platelet ability to translate mRNA in new proteins, they were loaded with [
35 S]-methionine and then cultured in the absence or presence of both fibrinogen and thrombin. As shown in Figure 2B , several [
35 S]-methioninelabeled proteins were synthesized in activated platelets. Immunoprecipitation with an anti-COX-1-specific antibody yielded a [
35 S]-methionine-labeled protein corresponding to the exact COX-1 size.
In conclusion, signal-dependent de novo synthesis of COX-1 occurring in aspirin-treated platelets after activation may represent a mechanism involved in the interference of complete and persistent suppression of TXA 2 biosynthesis by aspirin necessary for cardioprotection. The occurrence of this phenomenon in vivo in patients with cardiovascular disease treated with low-dose aspirin remains to be verified. Our results may contribute to shed some light on the rather nebulous concept of aspirin resistance.
